Using imipenem and cilastatin during continuous renal replacement therapy

Pharmacy World and Science

Volumn 27, Issue 5, 2005, Pages 371-375

  Cotton, Alison ^a   Franklin, Bryony Dean ^b   Brett, Stephen ^a   Holmes, Alison ^a  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Acute kidney failure; Cilastatin; Clearance; CRRT; Haemodialysis; Haemofiltration; Imipenem; Pharmacokinetics

Indexed keywords

CILASTATIN; IMIPENEM;

ACUTE KIDNEY FAILURE; CALCULATION; CHRONIC KIDNEY FAILURE; CONTINUOUS RENAL REPLACEMENT THERAPY; DRUG CLEARANCE; DRUG ELIMINATION; HEMODIALYSIS; HEMOFILTRATION; HUMAN; KIDNEY FAILURE; LIVER DYSFUNCTION; MAINTENANCE THERAPY; REVIEW;

ACUTE KIDNEY INJURY; ANTI-BACTERIAL AGENTS; CILASTATIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEMOFILTRATION; HUMANS; IMIPENEM; KIDNEY FAILURE, ACUTE; MALE; MIDDLE AGED; PROTEASE INHIBITORS;

EID: 28844499804     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-005-1636-x     Document Type: Review

References (17)

1. SR Norrby K Alestig F Ferber JL Huber KH Jones FM Kahan 1983a Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans Antimicrob Agents Chemother 23 293 9
2. SR Norrby K Alestig B Björnegård LA Burman F Ferber JL Huber 1983b Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by co-administration of of N-formimidoyl thienamycin dihydropeptidase inhibitor Antimicrob Agents Chemother 23 300 7
3. AHFS Drug Information. Bethesda: American Society of Health-System Pharmacists Inc., 2003. ISBN 1-58528-039-9
4. JD Rogers MAL Meisinger F Ferber GB Calendra JL Demetriades JA Bland 1985 Pharmacokinetics of imipenem/ cilastatin in volunteers Rev Infec Dis 7 Suppl 3 S435 46
5. GL Drussano HC Standiford 1985 Pharmacokinetic profile of imipenem/cilastatin in normal volunteers Am J Med 78 Suppl 6a 47 53
6. British National Formulary 46. London: British Medical Association & Royal Pharmaceutical Society Great Britain, Sept 2003. ISBN 0-85369-556-3
7. JA Kellum JP Johnson D Kramer 1998 Diffusive versus convective treatment: effects on mediators of inflammation in patients with severe systemic inflammatory response syndrome Crit Care Med 26 1995 2000
8. I Tegeder F Bremer R Oelkers H Schobel J Schüttler K Brune 1997 Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration Antimicrob Agents Chemother 41 12 2640 5
9. B Mueller SK Scarim WL Macias 1993 Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration Am J Kidney Dis 21 2 172 9
10. Hashimoto S, Honda M, Yamaguchi M, Sekimoto M, Tanaka Y. Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically iII. ASAIO J 1997; 84-8.
11. MC Vos HH Vincent EPF Yzerman 1992 Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD) Intensive Care Med 18 282 5
12. E Keller H Fecht J Böhler P Schollmeyer 1989 Single-dose kinetics of imipenem/cilastatin during continuous arteriovenous haemofiltration in intensive care patients Nephrol Dial Transplant 4 640 5
13. M Przechera D Bengel T Rider 1991 Pharmacokinetics of imipenem/cilastatin during continuous arteriovenous hemofiltration Contrib Nephrol 93 131 4
14. MG Dehne UR Kroh 1995 lmipenem/cilastin dosage during acute renal fialure and hemofiltration Intensive Care Med 21 863
15. M Kihara Y Ikeda K Shibata S Masumori H Ebira K Shiratori 1994 Clin Nephrol 42 3 193 97
16. Reeves DS. Human pharmacokinetics of N-formimidoylthienamycin alone and in combination with a dehydropeptidase inhibitor (MK-701) and probenecid. Proc 13th Int Congress Chemother 30-33
17. TP Gibson 1986 Renal disease and drug metabolism: an overview Am J Kidney Dis 8 7 17